Goldman Sachs’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,346,352
| Closed | -$222M | – | 6767 |
|
|
2021
Q2 | $222M | Buy |
1,346,352
+953,839
| +243% | +$159M | 0.05% | 358 |
|
|
2021
Q1 | $60.2M | Sell |
392,513
-82,045
| -17% | -$11.1M | 0.02% | 1019 |
|
|
2020
Q4 | $59.5M | Sell |
474,558
-52,466
| -10% | -$5.87M | 0.02% | 986 |
|
|
2020
Q3 | $53.5M | Sell |
527,024
-52,583
| -9% | -$5.36M | 0.02% | 942 |
|
|
2020
Q2 | $56.4M | Sell |
579,607
-42,731
| -7% | -$3.98M | 0.02% | 866 |
|
|
2020
Q1 | $51.7M | Buy |
622,338
+94,861
| +18% | +$9.25M | 0.02% | 836 |
|
|
2019
Q4 | $58.6M | Buy |
527,477
+125,517
| +31% | +$12.9M | 0.01% | 1029 |
|
|
2019
Q3 | $39.9M | Sell |
401,960
-350,202
| -47% | -$34.8M | 0.01% | 1266 |
|
|
2019
Q2 | $74.6M | Sell |
752,162
-37,577
| -5% | -$3.59M | 0.02% | 867 |
|
|
2019
Q1 | $87.1M | Sell |
789,739
-96,811
| -11% | -$10.1M | 0.03% | 745 |
|
|
2018
Q4 | $81.5M | Buy |
886,550
+35,239
| +4% | +$3.57M | 0.03% | 735 |
|
|
2018
Q3 | $93.8M | Sell |
851,311
-14,260
| -2% | -$1.48M | 0.02% | 807 |
|
|
2018
Q2 | $80.8M | Buy |
865,571
+87,105
| +11% | +$7.5M | 0.02% | 885 |
|
|
2018
Q1 | $64.6M | Buy |
778,466
+41,036
| +6% | +$3.65M | 0.02% | 1038 |
|
|
2017
Q4 | $67.2M | Buy |
737,430
+254,486
| +53% | +$21.2M | 0.02% | 1066 |
|
|
2017
Q3 | $36.8M | Buy |
482,944
+276,281
| +134% | +$20.9M | 0.01% | 1507 |
|
|
2017
Q2 | $15.5M | Sell |
206,663
-843,008
| -80% | -$58.4M | ﹤0.01% | 2154 |
|
|
2017
Q1 | $68.5M | Buy |
1,049,671
+161,246
| +18% | +$9.5M | 0.02% | 1013 |
|
|
2016
Q4 | $49M | Sell |
888,425
-47,084
| -5% | -$2.58M | 0.01% | 1285 |
|
|
2016
Q3 | $52.9M | Buy |
935,509
+278,367
| +42% | +$13.7M | 0.02% | 1165 |
|
|
2016
Q2 | $27.4M | Buy |
657,142
+384,236
| +141% | +$17.7M | 0.01% | 1563 |
|
|
2016
Q1 | $11.7M | Buy |
272,906
+250,153
| +1,099% | +$10.6M | ﹤0.01% | 2105 |
|
|
2015
Q4 | $1.03M | Buy |
+22,753
| New | +$956K | ﹤0.01% | 4267 |
|
|
2015
Q3 | – | Sell |
-49,682
| Closed | -$1.8M | – | 7571 |
|
|
2015
Q2 | $1.8M | Sell |
49,682
-10,640
| -18% | -$337K | ﹤0.01% | 3935 |
|
|
2015
Q1 | $1.74M | Buy |
+60,322
| New | +$1.68M | ﹤0.01% | 3929 |
|
Other funds holding PRAH
Goldman Sachs's PRAH Position: Q3 2021 in Review
Goldman Sachs sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 1,346,352 shares — an estimated $222M sold.
Goldman Sachs first reported a position in PRAH in Q1 2015 and held it in 25 quarters. The position peaked at $222M in Q2 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- Goldman Sachs reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Goldman Sachs sold 1,346,352 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $222M.
- Goldman Sachs first reported a position in PRA Health Sciences, Inc. in Q1 2015 and held it in 25 quarters.
- Goldman Sachs's PRA Health Sciences, Inc. position peaked at $222M in Q2 2021.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.